| Objective: To determine the expression levels of plasma BAFF in B cell malignancies, including acute lymphocytic leukemia (ALL), chronic lymph- ocytic leukemia (CLL), multiple myeloma (MM), Lymphoma patients. To compare the soluble BAFF before and after treatment, then analysis the relationship between plasma BAFF and clinical tumor burden indicators of B cell malignancies.Methods: The study included 41 cases of ALL, 34 cases of CLL, 42 cases of MM, 46 cases of Lymphoma patients and 15 cases of normal controls .There were 41 cases of ALL (24 males and 17 females, aging from 16 to 71, with a median age of 28), including 16 cases of untreated ALL, 8 cases of relapsed ALL and 17 cases of remissive ALL. There were 42 cases of MM (19 males and 23 females, aging from 41 to 85, with a median age of 57), including 13 cases of untreated MM, 20 cases of MM without remission and 8 cases of remissive MM. There were 46 cases of Lymphoma (25 males and 21 females, aging from 15 to 74, with a median age of 54), including17cases of untreated Lymphoma, and 24 cases of post-treatmemt Lymphoma. There were 34 cases of CLL (16 males and16 females, aging from 40 to 83, with a median age of 66), including 10 cases of untreated Lymphoma, and 22 cases of post-treatmemt Lymphoma. Taken 15 normal cases as controls (8 males and 7 females, aging from 18 to 69, with a median age of 42). The expression levels of plasma BAFF were messured by the ELISA. At the same time, we collected the clinical data to analyzeResults:1 The expression levels of plasma BAFF in the experimental groups1.1 The expression levels of plasma BAFF in untreated ALL were higher than those in control group (1513.156±191.211 VS 824.884±117.019, P<0.01),The expression levels of plasma BAFF in relapsed ALL were higher than those in control group (1617.669±164.218 VS 824.884±117.019, P<0.01), There were significant differences. The expression levels of plasma BAFF in remissive ALL were higher than those in control group (993.313±155.578 VS 824.884±117.019, P>0.05), The expression levels of plasma BAFF in untreated ALL were lower than those in relapsed group (1513.156±191.211 VS 1617.669±164.218, P>0.05), there were no significant differences. The expression levels of plasma BAFF in remissive ALL were lower than those in untreated group (993.313±155.578 VS 1513.156±191.211, P<0.01), The expression levels of plasma BAFF in remissive ALL were lower than those in relapsed group (993.313±155.578 VS 1617.669±164.218, P<0.01), there were signif- icant differences.1.2 The expression levels of plasma BAFF in untreated MM were higher than those in control group (1603.693±197.406 VS 824.884±117.019, P<0.01), The expression levels of plasma BAFF in MM without remission were higher than those in control group (1584.340±271.1214 VS 824.884±117.019, P<0.01), There were significant differences. The expression levels of plasma BAFF in remissive MM were higher than those in control group (909.183±118.353 VS 824.884±117.019, P>0.05), The expression levels of plasma BAFF in un-rem- issive group were lower than those in untreated MM (1584.340±271.121 VS 1603.693±197.406, P>0.05), there were no significant differences. The expression levels of plasma BAFF in remissive MM were lower than those in untreated group (909.183±118.353 VS 1603.693±197.406, P<0.01), The expr- ession levels of plasma BAFF in remissive MM were lower than those in the un-remissive group (909.183±118.353 VS 1584.340±271.121, P<0.01), there were significant differences.1.3 The expression levels of plasma BAFF in untreated Lymphoma were higher than those in control group (1592.208±162.594 VS 824.884±117.019, P<0.01), The expression levels of plasma BAFF in post-treatmemt Lymphoma were higher than those in control group (1302.012±183.685 VS 824.884±117.019, P<0.01), The expression levels of plasma BAFF in post-treatmemt Lymphoma were lower than those in untreated group (1302.012±183.685 VS 1592.208±162.594, P<0.01), There were significant differences.1.4 The expression levels of plasma BAFF in untreated CLL were higher than those in control group (1223.980±170.887 VS 824.884±117.019, P>0.05), The expression levels of plasma BAFF in post-treatmemt CLL were higher than those in control group (870.574±159.433 VS 824.884±117.019, P>0.05), There were no significant differences.The expression levels of plasma BAFF in post-treatmemt CLL were lower than those in untreated group (870.574±159.433 VS 1223.980±170.887, P<0.01), There was significant difference. 2 The level of BAFF in ALL group, MM group, Lymphoma and CLL group were negtively correlated with those of LDH, Spearman r were respectively:﹣0.046,﹣0.019, 0.173, 0.251 (P>0.05).3 The level of BAFF in ALL group and CLL group were positively correlated with those ofβ2-MG, Spearman r were respectively: 0.501, 0.664 (P<0.05). The level of BAFF in MM and Lymphoma group were negtively correlated with those ofβ2-MG, Spearman r were respectively: 0.177, 0.071 (P>0.05).4 The level of BAFF in MM group were positively correlated with those of median percentage of plasma cells in bone marrow of the MM, Spearman r was: 0.388 (P<0.05).5 The level of BAFF in MM group were negtively correlated with those of median serum immunoglobulin of the MM, Spearman r was: 0.105 (P>0.05).Conclusions:1 The plasma BAFF are highly expressed in the untreated or relapsed ALL, MM, Lymphoma group. These reveal that maybe the BAFF take part in the pathogenesis of B cell malignancies.2 The plasma BAFF are obviously decreased in the remissive ALL, remissive MM and post-treatmemt CLL. These reveal that BAFF change dynamically in different stages of B cell malignancies, and may be regarded as a therapy and prognosis indicator for ALL, MM, Lymphoma and CLL.3 The plasma BAFF are not obviously high expressed in the untreatment CLL, but the BAFF level in post-treatmemt CLL are higher than those in the normal control group, so we speculated that maybe BAFF play its role in B cell malignancies by taking part in the premature B cells.4 The plasma BAFF in ALL, MM, Lymphoma, CLL group are negtively correlated with LDH. The plasma BAFF in CLL group are positively correlated withβ2-MG, while other groups are negtively correlated withβ2-MG. The plasma BAFF in CLL group are positively correlated with the median percentage of plasma cells in bone marrow, while negtively correlated with Ig. We could not regard BAFF as a independent indicator to judge tumor burden and prognosis according to our recent experimental data. |
PDF Full Text Request